Genix Pharmaceuticals Issues Clarification to Previously Announced Private Placement Terms
Genix Pharmaceuticals (GENPF) corrected terms for a recently closed non‑brokered private placement announced earlier. The Company clarified the Unit issue price was $0.05 per Unit (not $0.10). The Company issued 2,000,000 Units at $0.05 for total gross proceeds of $100,000. Each Unit includes one common share and one transferable warrant. Each warrant permits purchase of one additional share at $0.10 per share and expires on September 4, 2027. All other private placement terms remain unchanged.
Genix Pharmaceuticals (GENPF) ha corretto i termini per una recente private placement non brokered annunciata in precedenza. L'azienda ha precisato che il prezzo di emissione dell'Unità era $0,05 per Unità (non $0,10). L'azienda ha emesso 2.000.000 Unità a $0,05 per un ammontare lordo totale di $100.000. Ogni Unità comprende una azione comune e un warrant trasferibile. Ogni warrant consente l'acquisto di una azione aggiuntiva a $0,10 per azione e scade il 4 settembre 2027. Tutti gli altri termini dell'offerta privata rimangono invariati.
Genix Pharmaceuticals (GENPF) corrigió los términos de una colocación privada reciente no brokered anunciada anteriormente. La empresa aclaró que el precio de emisión de la Unidad era $0,05 por Unidad (no $0,10). La empresa emitió 2.000.000 de Unidades a $0,05 por unidad para un ingreso bruto total de $100.000. Cada Unidad incluye una acción común y una warrant transferible. Cada warrant permite la compra de una acción adicional a $0,10 por acción y vence el 4 de septiembre de 2027. Todos los demás términos de la colocación privada permanecen sin cambios.
Genix Pharmaceuticals (GENPF)가 앞서 발표된 최근 비중개(private placement) 비공개 배정의 조건을 수정했습니다. 회사는 유닛 발행가가 $0.05 per Unit였으며($0.10가 아님)라고 명확히 밝혔습니다. 회사는 2,000,000 Units를 $0.05로 발행하여 총 총수익은 $100,000입니다. 각 유닛은 일반주 1주와 양도 가능한 워런트를 포함합니다. 각 워런트는 주당 추가 주식 1주를 $0.10에 구입할 수 있게 하며 만료일은 2027년 9월 4일입니다. 다른 비공개 배정 조건은 변경되지 않습니다.
Genix Pharmaceuticals (GENPF) a corrigé les termes d'une placement privé non intermédié récemment clôturé annoncé précédemment. La société a précisé que le prix d'émission de l'unité était $0,05 par unité (et non $0,10). La société a émis 2 000 000 d'unités à $0,05 par unité pour un produit brut total de $100 000. Chaque unité comprend une action ordinaire et un warrant transférable. Chaque warrant permet l'achat d'une action supplémentaire à $0,10 par action et expire le 4 septembre 2027. Tous les autres termes de la placement privé restent inchangés.
Genix Pharmaceuticals (GENPF) hat die Bedingungen einer kürzlich abgeschlossenen, nicht von einem Broker vermittelten Privatplatzierung korrigiert. Das Unternehmen hat klargestellt, dass der Ausgabepreis pro Einheit $0,05 pro Einheit betrug (nicht $0,10). Das Unternehmen emittierte 2.000.000 Einheiten zu $0,05 pro Einheit für einen Bruttoerlös von $100.000. Jede Einheit enthält eine Stammaktie und einen übertragbaren Warrants. Jeder Warrant erlaubt den Kauf einer zusätzlichen Aktie zu $0,10 pro Aktie und läuft am 4. September 2027 ab. Alle anderen Bedingungen der Privatplatzierung bleiben unverändert.
Genix Pharmaceuticals (GENPF) عدّلت شروط زيادة خاصة غير وسيطة أُعلنَت سابقاً. أوضحت الشركة أن سعر الإصدار للوحدة كان $0.05 للوحدة (وليس $0.10). صدرت الشركة 2,000,000 وحدة بسعر $0.05 للوحدة لإجمالي عوائد إجمالية قدرها $100,000. تتضمن كل وحدة سهماً واحداً عادياً ومTurnاً قابلاً للنقل. يتيح كل warrants شراء سهم إضافي بسعر $0.10 للسهم وتنتهي صلاحيته في 4 سبتمبر 2027. يبقى جميع شروط الجولة الخاصة الأخرى دون تغيير.
Genix Pharmaceuticals (GENPF) 对最近结束的非经纪私募发行的条款进行了修正。公司澄清单位发行价格为 $0.05/单位（不是 $0.10）。公司以 $0.05 的价格发行了 2,000,000 单位，总毛收益为 $100,000。每单位包含一股普通股和一张可转让的认股权证。每张认股权证允许以 $0.10 的价格购买一股额外股票，权证在 2027年9月4日到期。其他私募发行条款保持不变。
- Raised $100,000 gross proceeds from the placement
- Issued 2,000,000 Units to support near‑term financing needs
- Warrants provide potential additional cash if exercised at $0.10
- Immediate issuance of 2,000,000 new shares at $0.05
- Potential dilution from up to 2,000,000 warrant shares at $0.10
Vancouver, British Columbia--(Newsfile Corp. - October 7, 2025) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("GENIX" or the "Company") wishes to clarify an error in its news release dated September 04, 2025, regarding the Company's recently closed non-brokered private placement.
The previous release incorrectly stated that the Units were issued at a price of
Accordingly, the Company issued 2,000,000 units (each, a "Unit") at a price of
All other terms of the private placement remain unchanged.
About Genix
Genix Pharmaceuticals Corporation is a highly innovative Canadian ophthalmic drugs company. The Company focusses on the research, development, manufacture, licensing and sales of novel and innovative prescription and OTC ophthalmological products which meet the growing needs of consumers worldwide and especially the aging baby boomers. The Company has several products awaiting Health Canada approval.
On Behalf of the Board of Directors,
Mr. Mahmoud S. Aziz, President, Director
Genix Pharmaceuticals Corporation
www.genixpharm.com
For more information regarding Genix Pharmaceuticals Corporation, please contact:
Kevin Bottomley, Director
Tel: +1.604.609.6199
kbottomley@genixpharm.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as, "forward‐looking statements". Forward‐looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward‐looking statements, including without limitation those relating to the Company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward‐looking statements.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/269553
FAQ
What correction did Genix Pharmaceuticals (GENPF) announce on October 7, 2025?
How many Units did GENPF issue and what were the total gross proceeds?
What does each Unit in the GENPF private placement include?
What are the terms of the warrants issued by GENPF?
Will the corrected GENPF unit price change any other placement terms?
